A Clinical Study to Assess the Efficacy and Safety of DA-3002
A Clinical Study to Assess the Efficacy and Safety of DA-3002
A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin®.
Inclusion Criteria:

 -  Diagnosed with Turner's Syndrome through chromosome analysis

 -  The chronological age: 2≤AGE≤12

 -  The yearly growth rate should be less than 6cm; the bone age should be equal or less
 than 12; the height ≤ 10th percentile for the heights of their agemates

 -  Before the adolescence, Tuner stage I (breast)

 -  Normal thyroid function

 Exclusion Criteria:

 -  Growth hormone was administered for 12 months or longer in the past

 -  Treated with estrogen or adrenal androgens for 12 months or longer in the past

 -  Malignancy, CNS Trauma, Psychiatric Disorder